Psoriasis: A Biological and Behavioral Management Approach
Journal Title: Journal of Dermatology Research - Year 2023, Vol 4, Issue 3
Abstract
Psoriasis is characterized as a chronic inflammatory disease and while it is affecting a large percentage of the population worldwide it is linked to be triggered by a variety of reasons. It can be treated with topical, oral, intravenous, photochemotherapy, biologic agents or a combination of therapies, based on patient’s needs or skin severity. Most of these therapies can be expensive or even difficult to receive. The red scaly plaques on the skin alongside with the underlying symptoms can affect the wellbeing of patients. Areas such as the type of dermatological treatment which causes a psychological burden to patients once they are diagnosed with psoriasis, as well as the need of a multidisciplinary approach for the management of psoriasis are briefly discussed in this article.
Authors and Affiliations
Costeris Charalambos, Matheou Chrysanthi
Keywords
Related Articles
- EP ID EP721426
- DOI https://doi.org/10.46889/JDR.2023.4303
- Views 57
- Downloads 0
Antibodies Against Melanoma Antigens – Clinical and Therapeutical Markers
Melanoma-Associated Antigens (MAA) are correlated with tumor development, progression and metastatic dissemination. MAA can be targeted in immunotherapy by specific antibodies or by cytotoxic T-cells. MAA are actually se...
Recent Highlights and Expert Opinion on Psoriasis Management
Psoriasis is a common chronic inflammatory skin disorder characterized by red, flaky, crusty, scaly, itchy, thickened plaques (Fig. 1), which affects approximately 2% of the population worldwide [1-2]. Increasing evide...
A New Dermatological Research Focus in the Era of COVID-19 Pandemic
In the era of COVID-19 pandemic, the significance of skin manifestations is more important than we think. Dermatologists have a unique opportunity to adequately describe skin manifestations of COVID-19, and make our co...
Observed Causal Relationship Between Eczema and Inflammatory Bowel Diseases
Over the past 27 years in my functional medicine clinical practice, I have had 10 or more patients present with chronic and acute cases of eczema. After taking a thorough history, ordering blood tests and food intoleranc...
Open-Label Crossover Oral Bioequivalence Pharmacokinetics Comparison of a Single Dose of Super-bioavailable Itraconazole 130 mg and Innovator SUBA®-Itraconazole Capsules 130 mg (2 x 65 mg) in Healthy Adults Under Fed Conditions
Introduction: Itraconazole (ITZ), an antifungal agent taken orally, demonstrates intricate and variable absorption kinetics, significantly impacted by food intake. The invention of Super-Bioavailable Itraconazole (SITZ)...